Skip to content

Study · Not a test of the peptide alone · 2025

3 results

Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.

Yavuz E, Sağır MS, Ercan A, Erginer M, Barlas FB, Sakarya D, Kılıç Ş, Ölçeroğlu B, Yardibi H, Kalaycılar İB, Demiröz A

International journal of biological macromolecules25 Sept 2025

PMID41015370 (opens in a new tab)DOI10.1016/j.ijbiomac.2025.147888 (opens in a new tab)PepBankPUB-41015370
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome

    In rats with a sciatic nerve defect, a decellularized plant-based conduit with controlled IGF‑1 LR3 release significantly improved axonal regeneration.

    In plain wordsIn rats with a sciatic nerve defect, a plant-based nerve conduit that released IGF‑1 LR3 improved nerve fiber regrowth.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseAxonal regeneration
    Study

    ratn: not reported in source

    1 cm sciatic nerve defect
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The IGF-1 LR3-controlled releasing decellularized conduit significantly improved axonal regeneration and showed comparable performance to autologous nerve grafts, without inducing systemic toxicity.
    1 context sentence
    Summary · context
    Thirty rats were assigned to six experimental groups (n = 5) and underwent a 1 cm sciatic nerve defect.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome

    In rats with a sciatic nerve defect, the IGF‑1 LR3-releasing conduit performed comparably to autologous nerve grafts.

    In plain wordsIn rats with a sciatic nerve defect, the IGF‑1 LR3-releasing conduit performed about as well as a nerve graft taken from the same animal.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeRegeneration versus autologous nerve graft
    Study

    ratn: not reported in source

    1 cm sciatic nerve defect
    Comparator
    Autologous nerve graft
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    showed comparable performance to autologous nerve grafts, without inducing systemic toxicity.
    1 context sentence
    Summary · context
    Thirty rats were assigned to six experimental groups (n = 5) and underwent a 1 cm sciatic nerve defect.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  3. 03AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Safety outcome

    In rats with a sciatic nerve defect, the IGF‑1 LR3-releasing conduit did not induce systemic toxicity.

    In plain wordsIn rats with a sciatic nerve defect, the IGF‑1 LR3-releasing conduit did not cause toxicity throughout the body.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeSystemic toxicity
    Study

    ratn: not reported in source

    1 cm sciatic nerve defect
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    without inducing systemic toxicity.
    1 context sentence
    Summary · context
    Thirty rats were assigned to six experimental groups (n = 5) and underwent a 1 cm sciatic nerve defect.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.